104 related articles for article (PubMed ID: 2880839)
1. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.
Babiker IE
J Clin Psychiatry; 1987 Mar; 48(3):94-7. PubMed ID: 2880839
[TBL] [Abstract][Full Text] [Related]
2. Relapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
Glazer WM; Ereshefsky L
J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
[TBL] [Abstract][Full Text] [Related]
4. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
Johnson DA
J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
6. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
7. Depot neuroleptic therapy: an underutilized treatment option.
Glazer WM; Kane JM
J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
[TBL] [Abstract][Full Text] [Related]
8. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
9. The attitude of patients towards antipsychotic depot treatment.
Heres S; Schmitz FS; Leucht S; Pajonk FG
Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
[TBL] [Abstract][Full Text] [Related]
10. The subjective experiences of people who regularly receive depot neuroleptic medication in the community.
Phillips L; McCann E
J Psychiatr Ment Health Nurs; 2007 Sep; 14(6):578-86. PubMed ID: 17718731
[TBL] [Abstract][Full Text] [Related]
11. The natural course of schizophrenia and effective maintenance drug treatment.
Davis JM; Andriukaitis S
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):2S-10S. PubMed ID: 2870087
[TBL] [Abstract][Full Text] [Related]
12. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
14. Choice of maintenance medication for schizophrenia.
Davis JM; Chen N
J Clin Psychiatry; 2003; 64 Suppl 16():24-33. PubMed ID: 14680416
[TBL] [Abstract][Full Text] [Related]
15. [Modification of long-term schizophrenia by somato-therapeutic measures].
Gross G; Huber G; Schüttler R
Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621
[TBL] [Abstract][Full Text] [Related]
16. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
Ereshefsky L; Mascarenas CA
J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
[TBL] [Abstract][Full Text] [Related]
18. Long-acting injectables and risk for rehospitalization among patients with schizophrenia in the home care program in Taiwan.
Ju PC; Chou FH; Lai TJ; Chuang PY; Lin YJ; Yang CW; Tang CH
J Clin Psychopharmacol; 2014 Feb; 34(1):23-9. PubMed ID: 24145217
[TBL] [Abstract][Full Text] [Related]
19. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
20. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
